oral vs subq semaglutide Assessment of noninferiority of subcutaneous semaglutide: a systematic review and meta-analysis Oral Semaglutide at a Dose

Two factors compound: drug exposure scales with body weight (lighter body = more drug per pound), and physiological response varies by metabolic and cardiovascular phenotype

In the placebo group, patients who lost more than 5% of their body weight unexpectedly showed higher rates of major cardiovascular events, likely due to unintentional weight loss from underlying illness

Engage in shared decision-making: Balance aspiration risk with glycaemic control, especially in patients with type 2 diabetes

Tian, H., Zheng, X

The clinical challenge is to deliver sufficient quantities of antioxidants noninvasively, after Cl(2) exposure, to decrease morbidity and mortality